Baseline characteristics of the derivation cohort
| Characteristics | All patients (n=1827) | Compensated (n=1490) | Decompensated (n=337) | P value* |
| Age | 55 (45.9–62.7) | 54.6 (44.3–62) | 57.6 (51.1–64) | <0.001 |
| Male | 1140 (62.4) | 909 (61.0) | 231 (68.5) | 0.010 |
| BMI (kg/m2) | 26.5 (23.2–30.6) | 26.7 (23.2–30.9) | 25.9 (22.9–29.4) | 0.038 |
| Scores | ||||
| MELD score | 8 (6–10) | 7 (6–9) | 13 (9–17) | <0.001 |
| Child Pugh score | 5 (5–6) | 5 (5–5) | 8 (6–9) | <0.001 |
| Child Pugh class (A/B/C) | 1334/206/44 (84.2/13.0/2.8) | 0/1241/77 (0.0/94.2/5.8) | 93/129/44 (35.0/48.5/16.5) | <0.001 |
| SWE at baseline (kPa) | 11.8 (7.4–24.5) | 9.7 (6.9–17.3) | 30.3 (19.3–41.1) | <0.001 |
| TE at baseline (kPa) | 8.3 (5.7–14.0) | 8.3 (5.7–13.9) | 23.4 (12.6–35.7) | 0.017 |
| Aetiology: Alcohol/NAFLD/HCV/HBV/other or multiple causes | 414/389/267/166/310 (26.8/25.2/17.3/10.7/20.0) | 319/359/195/142/292 (24.6/27.7/15.0/10.9/21.8) | 95/30/72/24/28 (38.2/12.0/28.9/9.6/11.2) | <0.001 |
| Laboratory test | ||||
| Albumin (g/L) | 40.0 (33.8–43.0) | 41.0 (37.0–43.8) | 31.0 (26.0–36.6) | <0.001 |
| Alkaline phosphatase (U/L) | 90.0 (67.0–128.0) | 84.0 (64.8–114.0) | 132.0 (97.0–186.0) | <0.001 |
| ALT (U/L) | 44.9 (28.0–77.0) | 47 (28.3–80) | 38 (25–61) | <0.001 |
| AST (U/L) | 43.0 (30.0–69.0) | 40 (28.6–67) | 54 (38–80) | <0.001 |
| Bilirubin (mg/dL) | 0.8 (0.5–1.3) | 0.7 (0.5–1.1) | 1.6 (1–3.1) | <0.001 |
| Creatinine (mg/dL) | 0.8 (0.7–1.0) | 0.8 (0.7–1) | 0.8 (0.7–1.2) | 0.002 |
| INR | 1.1 (1.0–1.2) | 1 (1–1.1) | 1.3 (1.2–1.5) | <0.001 |
| Platelets (G/L) | 179 (122–242) | 194 (143–253) | 100 (70–149) | <0.001 |
| WCC (×109/L) | 6.2 (5.0–7.9) | 6.2 (5–7.9) | 6.3 (4.5–8.6) | 0.935 |
| CRP | 2.9 (1.1–7.0) | 2.3 (0.9–5.6) | 10 (5.2–28.4) | <0.001 |
| Score for liver fibrosis or cirrhosis | ||||
| ALBI | −2.63 (−2.96–-1.74) | −2.75 (−3.01–-2.21) | −1.59 (−2.24–-1.03) | <0.001 |
| FIB-4 | 1.96 (1.11–3.97) | 1.66 (1.00–2.97) | 5.19 (3.11–8.61) | <0.001 |
| APRI | 0.58 (0.32–1.23) | 0.50 (0.30–0.96) | 1.28 (0.69–2.40) | <0.001 |
| Clinical parameters | ||||
| Absence or abstinence of alcohol consumption | 1394 (76.3) | 560 (37.6) | 97 (28.8) | <0.001 |
| HCV SVR before SWE | 81 (16.8) | 74 (16.8) | 7 (16.3) | 1.000 |
| Previous variceal bleeding | 113 (6.9) | 69 (4.6) | 44 (13.1) | <0.001 |
| Previous bacterial infection | 99 (6.0) | 54 (3.6) | 45 (13.4) | <0.001 |
| Previous hepatorenal syndrome | 51 (3.1) | 20 (1.3) | 31 (9.2) | <0.001 |
*P value of the comparison between compensated and decompensated patients
†
ALBI, albumin-bilirubin score; ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet count ratio index; AST, aspartate aminotransferase; BMI, body mass index; CRP, C reactive protein; FIB-4, fibrosis-4 index; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio ; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease; SVR, sustained virologic response; SWE, shear wave elastography; TE, transient elastography; WCC, white cell count.